Latest Hospitality News

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

Orthocell has appointed a second Canadian distributor for its nerve repair device Remplir™, achieving full national coverage and setting the stage for initial sales this quarter.

Imricor Medical Systems and Amsterdam UMC have completed the first-ever ischemic ventricular tachycardia ablation fully guided by real-time MRI, marking a major advance in cardiac electrophysiology.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

HealthCo Healthcare & Wellness REIT confirms full collection of deferred and current rent from Healthscope, while advancing conditional agreements with alternative tenants for its hospital portfolio.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Adherium Limited reports a strong quarter with a 55% increase in device shipments and groundbreaking clinical results from its iCARE study, alongside securing over $2.6 million in post-quarter funding.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.